Insilico Medicine inks $2.75B AI drug deal with Eli Lilly, CEO hails Lilly's AI prowess

AI drug developer Insilico Medicine has secured a major commercialization deal with pharmaceutical giant Eli Lilly, a pact valued at up to $2.75 billion. The agreement, announced Sunday, grants Lilly the rights to develop, manufacture, and commercialize a portfolio of Insilico's preclinical drug candidates discovered using its artificial intelligence platform. The deal includes an upfront payment of $115 million to Insilico, with the remaining billions contingent on achieving future regulatory and commercial milestones.

Insilico CEO Alex Zhavoronkov's effusive praise for Lilly underscores the strategic significance of the partnership. Zhavoronkov, who is a user of Lilly's blockbuster drug tirzepatide (marketed as Mounjaro and Zepbound), declared that "Lilly is better in AI than Insilico, and no other company is better in AI than us … except for these guys." He insisted his admiration was genuine and long-standing, not merely a product of the new deal, calling tirzepatide "the best drug ever invented by humans" and expressing a desire to "develop the next one."

The deal represents a significant validation for Insilico's AI-driven discovery platform and a strategic move for Lilly to bolster its pipeline with novel, AI-generated assets. It signals the deepening integration of artificial intelligence into mainstream pharmaceutical R&D, where big pharma is increasingly partnering with or acquiring tech-native biotechs to accelerate drug discovery. The success of the partnership now hinges on translating these preclinical AI discoveries into clinical and commercial successes, with billions in potential payouts on the line.